

# Christine Longvert

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8020427/publications.pdf>

Version: 2024-02-01

21  
papers

283  
citations

1163117

8  
h-index

888059

17  
g-index

21  
all docs

21  
docs citations

21  
times ranked

491  
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of the French COVID-19 pandemic lockdown on newly diagnosed melanoma delay and severity. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	2.4	22
2	Second primary cutaneous melanoma in patients with advanced melanoma treated with anti-programmed cell death receptor-1 monoclonal antibodies. <i>British Journal of Dermatology</i> , 2021, 184, 746-748.	1.5	1
3	Treatment strategies and safety of rechallenge in the setting of immune checkpoint inhibitors-related myositis: a national multicentre study. <i>Rheumatology</i> , 2021, 60, 5753-5764.	1.9	17
4	Impact of prior treatment with immune checkpoint inhibitors on dacarbazine efficacy in metastatic melanoma. <i>British Journal of Cancer</i> , 2021, 125, 948-954.	6.4	11
5	Carpal Tunnel Syndrome: A New Adverse Effect of Immune Checkpoint Inhibitors, 11 Cases. <i>Journal of Immunotherapy</i> , 2021, 44, 122-126.	2.4	5
6	Efficacy of late concurrent hypofractionated radiotherapy in advanced melanoma patients failing anti-PD-1 monotherapy. <i>International Journal of Cancer</i> , 2020, 147, 1707-1714.	5.1	14
7	Incidence and Clinical Impact of Anti-TNF $\alpha$ Treatment of Severe Immune Checkpoint Inhibitor-induced Colitis in Advanced Melanoma: The Mecolit Survey. <i>Journal of Immunotherapy</i> , 2019, 42, 175-179.	2.4	57
8	Pembrolizumab and concurrent hypo-fractionated radiotherapy for advanced non-resectable cutaneous squamous cell carcinoma. <i>European Journal of Dermatology</i> , 2019, 29, 636-640.	0.6	12
9	Hyponatremia and MAPK kinase inhibitors in malignant melanoma: Frequency, pathophysiological aspects and clinical consequences. <i>Pigment Cell and Melanoma Research</i> , 2019, 32, 326-331.	3.3	5
10	Efficacy of hypofractionated radiotherapy (Rx) in melanoma patients who failed anti-PD-1 monotherapy: Assessing the abscopal effect.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9537-9537.	1.6	8
11	Efficacy of combined hypo-fractionated radiotherapy and anti-PD-1 monotherapy in difficult-to-treat advanced melanoma patients. <i>Oncolmmunology</i> , 2018, 7, e1442166.	4.6	57
12	On/off dropped head syndrome: A severe adverse event after prolonged treatment with MEK inhibitor. <i>European Journal of Cancer</i> , 2018, 91, 174-176.	2.8	2
13	Discontinuation of anti-PD-1 mAb after complete response in advanced melanoma pts.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21549-e21549.	1.6	1
14	Efficacy of combined hypofractionated radiotherapy and anti-PD-1 monotherapy in patients with melanoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, e21008-e21008.	1.6	2
15	Increase in NRAS mutant allele percentage during metastatic melanoma progression. <i>Experimental Dermatology</i> , 2016, 25, 472-474.	2.9	8
16	Reply to the letter to the editor "Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumor response and tolerance" by Funck-Brentano et al.. <i>Annals of Oncology</i> , 2016, 27, 364-365.	1.2	6
17	Relapsing pneumonitis due to two distinct inhibitors of the MAPK/ERK pathway: report of a case. <i>BMC Cancer</i> , 2015, 15, 732.	2.6	7
18	Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance. <i>Annals of Oncology</i> , 2015, 26, 1470-1475.	1.2	46

#	ARTICLE	IF	CITATIONS
19	Treatment of dermatofibrosarcoma protuberans (DFSP) with fixed Mohs micrographic surgery (f-MMS).. Journal of Clinical Oncology, 2015, 33, e20066-e20066.	1.6	1
20	Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: Impact on tumor response and tolerance.. Journal of Clinical Oncology, 2014, 32, 9016-9016.	1.6	0
21	Prognostic value of BRAFV600 mutations in melanoma patients after resection of metastatic lymph nodes.. Journal of Clinical Oncology, 2012, 30, 8540-8540.	1.6	1